PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU
PTC Therapeutics, Inc. (NASDAQ:PTCT) is reinforcing its position in rare disease innovation with the launch of SUFIANCE (sepiapterin) for phenylketonuria (PKU).
Ptc Therapeutics Inc. (PTCT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 4,735,464 | $231,280,062 | -13% | 3.99% |
| 2. | D E Shaw D. E. Shaw | 2,437,697 | $119,057,122 | +69% | 0.08% |
| 3. | Tang Capital Management Kevin C. Tang | 1,100,000 | $53,724,000 | +10% | 2.72% |
| 4. | Driehaus Capital Richard Driehaus | 1,059,026 | $51,722,830 | -30% | 0.41% |
| 5. | Renaissance Technologies Jim Simons | 963,300 | $47,047,572 | +44% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.81 | 7,700 | $198,736.23 | 33,700 | 2023-12-12 | Filing | |
| $32.48 | 10,000 | $324,846.00 | 100,066 | 2020-03-16 | Filing | |
| $30.20 | 66,225 | $1,999,995.00 | 1,386,594 | 2019-01-25 | Filing | |
| $13.49 | 25,000 | $337,230.00 | 25,000 | 2017-05-23 | Filing | |
| $6.23 | 2,000 | $12,460.00 | 5,125 | 2016-03-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $64.97 | 312 | $20,270.64 | 103,901 | 2025-10-07 | Filing | |
| $63.80 | 1,306 | $83,322.80 | 104,213 | 2025-10-07 | Filing | |
| $62.89 | 1,757 | $110,497.73 | 105,519 | 2025-10-07 | Filing | |
| $66.89 | 1,884 | $126,020.76 | 10,332 | 2025-10-03 | Filing | |
| $66.10 | 4,037 | $266,845.70 | 12,216 | 2025-10-03 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 503,966 | $30,928,393 | 0.08% | |
| 2. | 284,891 | $17,483,761 | 0.02% | |
| 3. | 107,648 | $6,606,358 | 0.01% | |
| 4. | 8,839 | $542,449 | 0.01% | |
| 5. | 7,620 | $467,639 | 0% |
News See All
11 Best Performing Biotech Stocks So Far in 2025
On July 8, Jared Holz of Mizuho spoke on CNBC's "Closing Bell Overtime" about whether the biotech sector is ready for a breakthrough.
11 Cheap Biotech Stocks to Buy According to Hedge Funds
Mizuho's Jared Holz appeared on CNBC's "Closing Bell Overtime" on July 8 to talk about whether the biotech industry is prepared for a breakthrough.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q2 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to PTC Therapeutics Second Quarter 2025 Earnings Conference Call. [Operator Instructions] Today's call is being recorded.
Truist Initiates PTC Therapeutics (PTCT) Coverage with Buy Rating on Drug Launches
PTC Therapeutics, Inc. (NASDAQ:PTCT) is one of the 10 biotech stocks screaming a buy.
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF.
Billionaire David E. Shaw's 10 Small-Cap Stock Picks with Huge Upside Potential
David E. Shaw is one billionaire investor whose record speaks for itself on Wall Street. Having founded D.E. Shaw & Co., L.P.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to the PTC Therapeutics First Quarter 2025 Earnings Conference Call. [Operator Instructions] Today’s conference is being recorded.
11 Best Gene Therapy Stocks to Buy According to Analysts
Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.
Hedge Fund Resource Center Billionaire Hedge Funds
